Source link : https://news.google.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?oc=5
Author :
Publish date : 2024-11-15 08:00:00
Copyright for syndicated content belongs to the linked Source.
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM) – Business Wire
ADVERTISEMENT
ADVERTISEMENT
